Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:SELB

Selecta Biosciences (SELB) Stock Price, News & Analysis

Selecta Biosciences logo

About Selecta Biosciences Stock (NASDAQ:SELB)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.88
$1.26
52-Week Range
N/A
Volume
2.77 million shs
Average Volume
979,585 shs
Market Capitalization
$136.76 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive SELB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Selecta Biosciences and its competitors with MarketBeat's FREE daily newsletter.

SELB Stock News Headlines

A grave, grave error.
Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the key to unlocking technological breakthroughs we once thought were impossible. And it may just be the only thing capable of bringing America back from the brink of recession – despite Washington’s incompetence and addiction to reckless spending. That’s why Elon Musk, Jeff Bezos, Jensen Huang, and even Bill Gates are pouring billions into the infrastructure behind it.
Cartesian Therapeutics Inc (RNAC)
See More Headlines

SELB Stock Analysis - Frequently Asked Questions

Selecta Biosciences, Inc. (NASDAQ:SELB) posted its earnings results on Thursday, August, 17th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.12) by $0.05. The company earned $5.25 million during the quarter, compared to analysts' expectations of $9.90 million. Selecta Biosciences had a negative net margin of 72.04% and a negative trailing twelve-month return on equity of 44.13%.
Read the conference call transcript
.

Selecta Biosciences (SELB) raised $64 million in an initial public offering on Wednesday, June 22nd 2016. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. UBS Investment Bank and Stifel served as the underwriters for the IPO and Canaccord Genuity and Needham & Company were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Selecta Biosciences investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), GE Aerospace (GE), Pfizer (PFE), CrowdStrike (CRWD).

Company Calendar

Last Earnings
8/17/2023
Today
7/01/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:SELB
Employees
64
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$35.38 million
Pretax Margin
-73.23%

Debt

Sales & Book Value

Annual Sales
$110.78 million
Price / Cash Flow
9.91
Book Value
$0.61 per share
Price / Book
N/A

Miscellaneous

Free Float
106,780,000
Market Cap
$136.76 million
Optionable
Optionable
Beta
0.84

Social Links

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

This page (NASDAQ:SELB) was last updated on 7/1/2025 by MarketBeat.com Staff
From Our Partners